Events & Presentations

Upcoming Events
More events are coming soon.
Archived Events
Date Event Details
May 10, 2022 4:30 PM EDT
Arrowhead Pharmaceuticals 2022 Second Quarter Results
May 9 - May 12, 2022
TIDES USA 2022: Oligonucleotide and Peptide Therapeutics
Title: Arrowhead’s Approach to Oligonucleotide Scale-Up Manufacturing
Presenter: Michael Lawler, Director, Chemistry, Arrowhead Pharmaceuticals
Apr 25 - Apr 27, 2022
DIA/FDA's Oligonucleotide-based Therapeutics Conference (Oligo22)

Title: Short Interfering RNA JNJ-3989 Combination Therapy
Presenter: Michael Biermer, Senior Director, Clinical Development, Janssen Pharmaceuticals

Title: ARO-HIF2 Evaluated in Clear Cell Renal Cell Carcinoma Ph1b Clinical Trial
Presenter: James Hamilton, Senior Vice President, Discovery and Translational Medicine, Arrowhead Pharmaceuticals

Apr 8 - Apr 13, 2022
American Association for Cancer Research Annual Meeting 2022 (AACR)
Title: Targeting HIF2a with siRNA: From preclinical models to the clinic
Authors: Yuanqing Ma, et al.
Mar 30 - Apr 3, 2022
31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022)

Title: Pharmacokinetics and Safety of JNJ-73763989, an RNA Interference Therapy for Hepatitis B Virus, in Moderately Hepatically Impaired Participants
Authors: Thomas N. Kakuda, et al.

Title: Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in
Healthy Chinese Adult Participants

Authors: Haiyan Li, et al.

Title: Short interfering RNA JNJ-3989 combination therapy in chronic 
hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors

Authors: Edward Gane, et al.

Feb 17 - Feb 19, 2022
2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
San Francisco, CA and online

Presentation Details: Title:

Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001) Authors: James Brugarolas, et al. Session: Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers Abstract Number: 339 Poster Number: F9
Feb 2, 2022 4:30 PM EST
Arrowhead Pharmaceuticals 2022 First Quarter Results
Dec 3, 2021
18th Global Cardiovascular Clinical Trialists Forum
James Hamilton, MD, MBA, Arrowhead’s senior vice president of discovery & translational medicine, will participate in a panel discussion titled, “Developments in Hypertriglyceridemia Trials”
Dec 2, 2021 1:00 PM EST
4th Annual Evercore ISI HealthCONx Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Nov 30, 2021
Piper Sandler 33rd Annual Healthcare Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation